AzTrials
AzTrials

Metastatic Pancreatic AdenocarcinomaPhase 1NCT02671890

Disulfiram and Chemotherapy in Treating Patients With Refractory Solid Tumors or Metastatic Pancreatic Cancer

A Phase 1 study testing Chemotherapy, Disulfiram and Gemcitabine Hydrochloride in people with Metastatic Pancreatic Adenocarcinoma and Refractory Malignant Solid Neoplasm, run by Mayo Clinic at 2 sites in United States.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

This partially randomized phase I trial studies the side effects and best dose of disulfiram when given together with chemotherapy in treating patients with a solid tumor that does not respond to treatment (refractory) or pancreatic cancer that has spread to other places in the body (metastatic) and to compare whether… Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Chemotherapy, Disulfiram and Gemcitabine Hydrochloride
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
16 participants
Where
2 sitesUnited States
Study dates
25 Feb 2016to 11 Nov 2024
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Cohort 1 (dose escalation): histologic or cytologic proof of any solid tumor that is incurable with no standard therapy that is likely to make a major impact on clinical outcomes
  • Cohort 2 (MTD) only: metastatic adenocarcinoma of the pancreas; prior systemic treatment for metastatic disease is allowed
  • Cohort 2 (MTD) only: Patient is thought to be a short- or long-term candidate for chemotherapy in the opinion of the treating oncologist
  • Absolute neutrophil count (ANC) >= 1500/mm^3 (obtained =< 7 days prior to registration)
  • Platelet >= 100,000/ mm^3 (obtained =< 7 days prior to registration)
  • Total bilirubin =< 2 x upper limit of normal (ULN) (obtained =< 7 days prior to registration)
Show all 39Show fewer
  • Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) =< 3 x ULN (obtained =< 7 days prior to registration)
  • Creatinine =< 1.5 x ULN (obtained =< 7 days prior to registration)
  • Hemoglobin >= 9.0 g/dL (obtained =< 7 days prior to registration)
  • Cohort 2 (MTD) only: prothrombin time (PT)/international normalized ratio (INR) =< 1.5 x ULN (only if muscle biopsy has not been waived, does not apply to non-Mayo sites that will not be conducting biopsies) (obtained =< 7 days prior to registration)
  • Ability to provide written informed consent
  • Life expectancy >= 12 weeks
  • Cohort 2 (MTD) only: patient willing to undergo muscle biopsies at baseline and after 28 to 35 days of disulfiram/chemotherapy as required by the protocol unless the muscle biopsy has been waived after discussion with the principal investigator (PI); muscle biopsies will not be required at non-Mayo Clinic sites
  • Cohort 2 (MTD) only: patient willing to have paraffin-embedded slides of the primary pancreas tumor or metastatic site, if available, sent to Mayo investigators for this study
  • For women of childbearing potential only: negative urine or serum pregnancy test done =< 7 days prior to registration
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2
  • Able to swallow or have medication administered through a gastrostomy tube (G-tube) and absorb the medication
  • Patient willing to complete a medication diary
  • Patient agrees to use acceptable form of contraception during the study and for up to 30 days after last study drug dose if female partner is of childbearing potential
  • Acceptable forms of contraception:
  • Latex condom (always used with spermicide)
  • Diaphragm (always used with spermicide)
  • Cervical cap (always used with spermicide)
  • Acceptable forms of secondary contraception, when used along with a barrier method:
  • Hormonal contraception methods, including pills, patches, rings, or injections except progestin-only containing pills (i.e. "Mini-pill")
  • Tubal ligation
  • Partner's vasectomy
  • Intrauterine device (non-progesterone T)
  • Vaginal sponge (containing spermicide)
  • Other acceptable forms:
  • 100% commitment to abstinence
  • Unacceptable forms of contraception for women of childbearing potential:
  • Oral contraception containing progestins only
  • Intrauterine device (IUD) progesterone T
  • Female condom
  • Natural family planning (rhythm method) or breastfeeding
  • Fertility awareness
  • Withdrawal
  • Cervical shield

Who cannot join

  • Known standard therapy for the patient's disease that is potentially curative
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, including localized infections, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia or psychiatric illness/social situations that would limit compliance with study requirements
  • Untreated brain metastases
  • Any of the following:
  • Pregnant women
  • Nursing women This study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown.
Show all 10Show fewer
  • Other concurrent chemotherapy, immunotherapy, radiotherapy, any ancillary therapy considered investigational (utilized for a non-Food and Drug Administration [FDA]-approved indication and in the context of a research investigation) or receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
  • Baseline of grade 2 or worse peripheral sensory neuropathy
  • Receiving phenytoin
  • Unable to abstain from alcohol for the duration of the study

Trial locations and contacts

2 sites in 1 country.

United States2 sites

  • Mayo Clinic in Rochester

    Rochester, Minnesota, 55905

  • Sanford Thief River Falls Medical Center

    Thief River Falls, Minnesota, 56701

Other trials in United States

About this study

Official title: Expansion Cohort Study of Disulfiram and Chemotherapy in Pancreas Cancer Patients

This partially randomized phase I trial studies the side effects and best dose of disulfiram when given together with chemotherapy in treating patients with a solid tumor that does not respond to treatment (refractory) or pancreatic cancer that has spread to other places in the body (metastatic) and to compare whether disulfiram and chemotherapy may reduce tumor induced muscle loss. Weight loss occurs in pancreatic cancer patients and is common in a multitude of other cancers. Patients with metastatic cancer and weight loss sometimes are not able to receive treatment due to physical weakness or debility. Disulfiram is a potential inhibitor of muscle degradation and may reduce tumor induced muscle wasting. Disulfiram may also help chemotherapy work better by making tumor cells more sensitive to the drug. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving chemotherapy with or without disulfiram is a better treatment for refractory solid tumors or metastatic pancreatic cancer.

Read the detailed description

PRIMARY OBJECTIVE:

  1. To determine the maximally tolerated dose (MTD) of the combination of disulfiram and gemcitabine (gemcitabine hydrochloride) in unresectable solid tumor cancer patients (Cohort 1).

SECONDARY OBJECTIVES:

  1. To describe the adverse event profile associated with this combination of disulfiram and chemotherapy (Cohort 2).

II. To describe changes in muscle area at the L3 level from baseline to 28 to 60 days from the baseline computed tomography (CT) scan in patients treated with disulfiram/chemotherapy and with placebo/chemotherapy (Cohort 2).

III. To describe changes in fist-grip strength from baseline to 28 to 35 days of treatment with disulfiram/gemcitabine and with placebo/chemotherapy (Cohort 2).

IV. To describe overall survival of pancreas cancer patients who disulfiram/chemotherapy or placebo/chemotherapy (Cohort 2).

  1. To estimate the response rate per Response Evaluation Criteria in Solid Tumors (RECIST) criteria around 1 month post-treatment in patients who receive disulfiram/chemotherapy and placebo/chemotherapy (Cohort 2).

CORRELATIVE OBJECTIVE:

  1. To assess the effect of disulfiram and chemotherapy on the ubiquitin proteasome and autophagy pathways within muscle, as assessed by means of muscle biopsies performed at baseline and after 28 to 35 days of treatment (Cohort 2) (this is for Mayo only patients and can be waived upon permission from the principal investigator [PI]).

OUTLINE: This is a phase I, dose-escalation study of disulfiram.

COHORT I: Patients receive gemcitabine hydrochloride intravenously (IV) over 30 minutes on days 1, 8, and 15 and disulfiram orally (PO) on days 1-28 or days 1-35.

COHORT II: Patients receive chemotherapy at the discretion of the treating oncologist and disulfiram PO on days 1-28 or days 1-35.

After completion of study treatment, patients are followed up at 30 days, and then every 6 months for 3 years.

Being tested
Chemotherapy, Disulfiram, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis
Medical subject headings
Pancreatic Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ChemotherapyDrug

    Also called Chemo, Chemotherapy (NOS), Chemotherapy, Cancer, General

  • DisulfiramDrug

    Also called Antabuse, DS, Tetraethylthioperoxydicarbonic Diamide, Teturamin

    Given PO

  • Gemcitabine HydrochlorideDrug

    Also called dFdCyd, Difluorodeoxycytidine Hydrochloride, FF 10832, FF-10832

    Given IV

  • Laboratory Biomarker AnalysisOther

    Correlative studies

Study groups in NCT02671890
Study groupRoleWhat they receive
Cohort I (gemcitabine hydrochloride and disulfiram)ExperimentalPatients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15 and disulfiram PO on days 1-28 or days 1-35.
Receives: Drug: Disulfiram; Drug: Gemcitabine Hydrochloride; Other: Laboratory Biomarker Analysis
Cohort II (chemotherapy and disulfiram)ExperimentalPatients receive chemotherapy at the discretion of the treating oncologist and disulfiram PO on days 1-28 or days 1-35.
Receives: Drug: Chemotherapy; Drug: Disulfiram; Other: Laboratory Biomarker Analysis

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Maximum tolerated dose (MTD) (Cohort I)

    MTD is defined as the dose level below the lowest dose that induces dose limiting toxicity (DLT) in at least one-third of patients (at least 2 of a maximum of 6 new patients).

    Measured: 28 days

Secondary outcomes (8)

  1. Adverse events profile (Cohort I and II)

    The number and severity of all adverse events (overall, by dose-level, and by tumor group) will be tabulated and summarized in this patient population. The grade 3+ adverse events will also be described and summarized in a similar fashion. This will provide an indication of the level of tolerance for this treatment combination in this patient group.

    Measured: Up to 30 days post-treatment

  2. Toxicity profile defined as adverse events that are classified as either possibly, probably, or definitely related to study treatment (Cohorts I and II)

    Non-hematologic toxicities will be evaluated via the ordinal Common Terminology Criteria (CTC) standard toxicity grading. Hematologic toxicity measures of thrombocytopenia, neutropenia, and leukopenia will be assessed using continuous variables as the outcome measures (primarily nadir) as well as categorization via CTC standard toxicity grading. Overall toxicity incidence as well as toxicity profiles by dose level, patient and tumor site will be explored and summarized. Frequency distributions, graphical techniques and other descriptive measures will form the basis of these analyses.

    Measured: Up to 30 days post-treatment

  3. Overall survival (OS) (Cohort I and II)

    OS will be summarized descriptively using the Kaplan-Meier estimate up to 3 years of follow-up in all alive patients.

    Measured: From registration until death due to any cause, assessed up to 3 years

  4. Change in muscle area at the L3 level using a computed tomography (CT) scan (Cohort II)

    Changes will be described using summary statistics and graphical techniques. A grayscale pixel histogram of the remaining muscle in the image will be constructed and summed. The number of pixels will then be converted to an area measurement in squared centimeters. All measurements and calculations for each image will be undertaken by two independent study personnel, and the average will be used in the analyses. A Wilcoxon rank sum test may be used as appropriate to compare percent changes of biomarkers between the muscle clinical responders and the non-responders based on CT scan measurements of muscle.

    Measured: Baseline to day 28

  5. Response rate (Cohort II)

    Response rate will be assessed using standard Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria.

    Measured: At 1 month post-treatment

  6. Change in muscle area at the L3 level using a computed tomography scan (Cohort II)

    Changes will be described using summary statistics and graphical techniques. A grayscale pixel histogram of the remaining muscle in the image will be constructed and summed. The number of pixels will then be converted to an area measurement in squared centimeters. All measurements and calculations for each image will be undertaken by two independent study personnel, and the average will be used in the analyses. A Wilcoxon rank sum test may be used as appropriate to compare percent changes of biomarkers between the muscle clinical responders and the non-responders based on CT scan measurements of muscle.

    Measured: Baseline to day 35

  7. Changes in fist-grip strength as measured by hand dynamometer (Cohort II)

    Changes will be described using summary statistics and graphical techniques. Patients will use 3 successive tries, and the average value will be used.

    Measured: Baseline to day 28

  8. Changes in fist-grip strength as measured by hand dynamometer (Cohort II)

    Changes will be described using summary statistics and graphical techniques. Patients will use 3 successive tries, and the average value will be used.

    Measured: Baseline to day 35

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 Feb 2016 (estimated)
  2. Study start25 Feb 2016
  3. Primary completion8 May 2024
  4. Study completion11 Nov 2024

Why it stopped: lack of funding

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
16 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02671890
Sponsor's protocol ID
MC1512
Other IDs
R01CA195473, NCI-2016-00007, 15-003194, MC1512
Status last verified
Jan 2025
First submitted
29 Jan 2016
Last updated
7 Jan 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing Chemotherapy, Disulfiram and Gemcitabine Hydrochloride in people with Metastatic Pancreatic Adenocarcinoma and Refractory Malignant Solid Neoplasm, run by Mayo Clinic at 2 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 39 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 7 Jan 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study was stopped early (reason given: lack of funding). Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Maximum tolerated dose (MTD) (Cohort I) (time frame: 28 days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02671890.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Jan 2025.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in